GTHX G1 Therapeutics Inc.

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It engages in developing novel, small-molecule therapies to target significant unmet needs to treat cancer.

$25.53  +0.30 (1.19%)
As of 04/09/2021 15:59:50 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/17/2017
Outstanding shares:  38,045,935
Average volume:  1,168,958
Market cap:   $972,834,558
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    3621LQ109
ISIN:        US3621LQ1099
Sedol:      BF0QXG9
Valuation   (See tab for details)
PE ratio:   -14.26
PB ratio:   5.50
PS ratio:   21.48
Return on equity:   -55.96%
Net income %:   -219.18%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy